Table 3.
Univariate analysis of variables associated with overall survival.
| Parameter | (median, IQR) | HR | (95%CI) | P value | |
|---|---|---|---|---|---|
| Age | ≤60 | (52, 8) | 0.007 | ||
| >60 | (68, 10) | 1.735 | (1.163,2.588) | ||
| Gender | Male | – | 0.705 | ||
| Female | – | 0.927 | (0.624,1.375) | ||
| ECOG PS | ≤1 | – | 0.001 | ||
| >1 | – | 1.888 | (1.278,2.789) | ||
| B symptom | Yes | – | 0.480 | ||
| No | – | 0.599 | (0.145,2.483) | ||
| Cell of origin | GCB | – | 0.088 | ||
| Non GCB | – | 0.555 | (0.282,1.091) | ||
| EBV | Negative | – | 0.481 | ||
| Positive | – | 2.047 | (0.280,14.989) | ||
| Treatment | Chemotherapy | – | – | – | 0.010 |
| Radiotherapy | – | 4.807 | (1.724,13.407) | ||
| CMT+RT | – | 1.250 | (0.676,2.311) | ||
| MSKCC | Low | – | – | – | 0.004 |
| Intermediate | – | 1.461 | (0.838,2.545) | ||
| High | – | 2.687 | (1.446,4.991) | ||
| LDH | ≤250 U/L | (179, 53) | 0.255 | ||
| >250 U/L | (384, 157) | 1.289 | (0.823,1.997) | ||
| NLR | ≤4.74 | (2.19, 1.46) | 0.023 | ||
| >4.74 | (7.28, 5.56) | 1.634 | (1.069,2.498) | ||
| dNLR | ≤3.29 | (1.66, 0.96) | 0.039 | ||
| >3.29 | (5.06, 3.27) | 1.568 | (1.023,2.405) | ||
| LLR | ≤166.8 | (110.75, 50.09) | 0.016 | ||
| >166.8 | (242.05, 195.36) | 1.710 | (1.105,2.646) | ||
| Neutrophil | ≤2.0×109/L | (1.76, 0.26) | 0.644 | ||
| >2.0×109/L | (5.05, 3.76) | 1.593 | (0.222,11.448) | ||
| Lymphocyte | ≤1.5×109/L | (1.05, 0.39) | 0.110 | ||
| >1.5×109/L | (2.10, 0.91) | 0.712 | (0.469,1.080) |
IQR, interquartile range; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B cell; EBV, Epstein-Barr virus; CMT, chemotherapy; RT, radiotherapy; MSKCC, Memorial Sloan Kettering Cancer Center; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to lymphocyte ratio; LLR, lactate dehydrogenase-to-lymphocyte ratio.